Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tissue Repair Ltd ( (AU:TRP) ) has provided an announcement.
Tissue Repair Ltd has notified the market of the cessation of a total of 416,227 options, comprising two classes of securities that lapsed on 27 February 2026 after the conditions attached to them were not met or became incapable of being satisfied. The expiry of these conditional rights slightly reduces the company’s pool of potential future equity, clarifying its issued capital structure for shareholders and may modestly affect expectations around future dilution and incentive alignment.
The company reported that 233,197 options expiring 27 September 2036 with an exercise price of $1.15 and 183,030 options expiring 15 November 2036, also exercisable at $1.15, have both lapsed under the same conditional framework. This administrative update refines the company’s long-dated option profile, offering greater transparency on capital management and potentially influencing how investors assess its long-term funding flexibility and equity-based remuneration plans.
The most recent analyst rating on (AU:TRP) stock is a Hold with a A$0.18 price target. To see the full list of analyst forecasts on Tissue Repair Ltd stock, see the AU:TRP Stock Forecast page.
More about Tissue Repair Ltd
Tissue Repair Ltd is an ASX-listed company (code TRP) operating in the biotechnology and medical sector, focused on developing tissue repair and regenerative treatments. The company’s activities center on creating and commercialising therapies designed to improve healing outcomes, positioning it within the broader healthcare and life sciences market.
Average Trading Volume: 121,495
Technical Sentiment Signal: Sell
Current Market Cap: A$10.88M
For detailed information about TRP stock, go to TipRanks’ Stock Analysis page.